Immunotherapy with NK cell, rituximab and rhu-GMCSF in non-myeloablative allogeneic stem cell transplantation.

Trial Profile

Immunotherapy with NK cell, rituximab and rhu-GMCSF in non-myeloablative allogeneic stem cell transplantation.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs Granulocyte colony-stimulating factors (Primary) ; Rituximab (Primary)
  • Indications B cell lymphoma; Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 08 Mar 2017 Planned End Date changed from 1 Sep 2012 to 1 Sep 2018.
    • 08 Mar 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018.
    • 03 Mar 2016 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top